Evidence map›Paper›PMID 38106097›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Acoustic enrichment of heterogenous circulating tumor cells and clusters from patients with metastatic prostate cancer.

Cecilia Magnusson, Per Augustsson, Eva Undvall Anand, Andreas Lenshof, Andreas Josefsson, Karin Welén, Anders Bjartell, Yvonne Ceder, Hans Lilja, Thomas Laurell

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Cecilia MagnussonDepartment of Translational Medicine, Lund University, Lund, Sweden.
Per AugustssonDepartment of Biomedical Engineering, Lund University, Lund, Sweden.
Eva Undvall AnandDepartment of Biomedical Engineering, Lund University, Lund, Sweden.
Andreas LenshofDepartment of Biomedical Engineering, Lund University, Lund, Sweden.
Andreas JosefssonIntitute of Clinical Sciences, Department of Urology, Gothenburg University, Gothenburg Sweden.
Karin WelénIntitute of Clinical Sciences, Department of Urology, Gothenburg University, Gothenburg Sweden.
Anders BjartellDepartment of Translational Cancer Research, Lund University, Lund, Sweden.
Yvonne CederDepartment of Laboratory Medicine, Lund University, Lund, Sweden.
Hans LiljaDepartment of Translational Medicine, Lund University, Lund, Sweden.
Thomas LaurellDepartment of Biomedical Engineering, Lund University, Lund, Sweden.
Lund University · SEUniversity of Gothenburg · SEMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: There are important unmet clinical needs to develop cell enrichment technologies to enable unbiased label-free isolation of both single cell and clusters of circulating tumor cells (CTCs) manifesting heterogeneous lineage specificity. Here, we report a pilot study based on microfluidic acoustophoresis enrichment of CTCs using the CellSearch CTC assay as a reference modality. Methods: Acoustophoresis uses an ultrasonic standing wave field to separate cells based on biomechanical properties (size, density, and compressibility) resulting in inherently label-free and epitope-independent cell enrichment. Following red blood cell lysis and paraformaldehyde fixation, 6 mL of whole blood from 12 patients with metastatic prostate cancer and 20 healthy controls were processed with acoustophoresis and subsequent image cytometry. Results: Acoustophoresis enabled enrichment and characterization of phenotypic CTCs (EpCAM Conclusion: Our preliminary data indicate that acoustophoresis provides excellent possibilities to detect and characterize CTC-clusters as a putative marker of metastatic disease and outcomes. Moreover, acoustophoresis enables sensitive label-free enrichment of cells with epithelial phenotype in blood and offers opportunities to detect and characterize CTCs undergoing epithelial-to-mesenchymal transitioning and lineage plasticity.

Indexed as

AcoustophoresisCirculating tumor cellsCTC-clusterlabel-freeProstate cancer

Identifiers

PMID38106097
PMCPMC10723509
OpenAlexW4389342209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.